We are live on ! Find out more
MURA

Mural Oncology

Delisted

MURA was delisted on the 4th of December, 2025.

101 hedge funds and large institutions have $59.9M invested in Mural Oncology in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 51 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8.27% less ownership

Funds ownership: 80.7%72.43% (-8.3%)

18% less funds holding

Funds holding: 123101 (-22)

25% less capital invested

Capital invested by funds: $79.7M → $59.9M (-$19.8M)

58% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 38

73% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 51

Holders
101
Holders Change
-22
Holders Change %
-17.89%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
16
Increased
14
Reduced
51
Closed
38
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SC
26
Shay Capital
New York
$367K -$2.29K -472 -0.6%
HF
27
HRT Financial
New York
$362K -$621K -127,839 -63%
Goldman Sachs
28
Goldman Sachs
New York
$331K -$284K -58,590 -46%
Charles Schwab
29
Charles Schwab
California
$318K -$78.3K -16,126 -20%
Arrowstreet Capital
30
Arrowstreet Capital
Massachusetts
$299K +$46.6K +9,597 +19%
Millennium Management
31
Millennium Management
New York
$296K -$782K -160,987 -73%
Citadel Advisors
32
Citadel Advisors
Florida
$285K -$922K -189,933 -77%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$271K -$1.67M -343,979 -86%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$234K -$15.7K -3,241 -6%
FLC
35
Fifth Lane Capital
Texas
$220K +$218K +45,000 New
Jane Street
36
Jane Street
New York
$213K +$23.6K +4,856 +13%
Marshall Wace
37
Marshall Wace
United Kingdom
$207K -$159K -32,715 -44%
T. Rowe Price Associates
38
T. Rowe Price Associates
Maryland
$204K +$75.7K +15,600 +60%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$189K -$970K -199,749 -84%
Aberdeen Group
40
Aberdeen Group
United Kingdom
$158K
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$117K -$602 -124 -0.5%
Canada Pension Plan Investment Board
42
Canada Pension Plan Investment Board
Ontario, Canada
$109K
AllianceBernstein
43
AllianceBernstein
Tennessee
$102K -$1.17K -241 -1%
UBS Group
44
UBS Group
Switzerland
$99.6K +$34.2K +7,055 +53%
Deutsche Bank
45
Deutsche Bank
Germany
$98.5K -$5.13K -1,057 -5%
LCS
46
Levin Capital Strategies
New York
$97.8K +$97.1K +20,000 New
JP Morgan Chase
47
JP Morgan Chase
New York
$96.2K -$75.2K -15,485 -44%
HCA
48
Harbor Capital Advisors
Illinois
$86K +$85.7K +17,653 New
HSBC Holdings
49
HSBC Holdings
United Kingdom
$65.1K +$64.6K +13,311 New
PNC Financial Services Group
50
PNC Financial Services Group
Pennsylvania
$59.5K -$16.6K -3,425 -22%

MURA Hedge Fund Activity: Q1 2024 in Review

101 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Mural Oncology (MURA) for Q1 2024, worth a combined $59.9M — down 25% from $79.7M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of MURA and 16 opened new positions — a net loss of 22 holders — while 51 trimmed existing stakes and 14 added.

The largest buyer was Solas Capital Management, opening a new position worth an estimated $3.64M. The largest seller was Vanguard Group, cutting an estimated $2.76M.

  • 101 institutional investors held Mural Oncology (MURA) as of Q1 2024, down from 123 in Q4 2023.
  • Funds reported $59.9M of Mural Oncology stock for Q1 2024, down 25% quarter-over-quarter.
  • 16 funds opened new Mural Oncology positions in Q1 2024 and 38 closed out, a net change of -22 holders.
  • The largest Mural Oncology buyer in Q1 2024 was Solas Capital Management, an estimated $3.64M added.
  • The largest Mural Oncology seller in Q1 2024 was Vanguard Group, an estimated $2.76M sold.

Based on aggregated 13F filings for Q1 2024.